Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
31.43
-0.85 (-2.63%)
Jan 17, 2025, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 927 employees as of February 15, 2024. The number of employees increased by 131 or 16.46% compared to the previous year.
Employees
927
Change (1Y)
131
Growth (1Y)
16.46%
Revenue / Employee
$866,307
Profits / Employee
-$387,067
Market Cap
4.96B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Feb 15, 2024 | 927 | 131 | 16.46% |
| Feb 16, 2023 | 796 | 136 | 20.61% |
| Feb 16, 2022 | 660 | -97 | -12.81% |
| Feb 18, 2021 | 757 | -60 | -7.34% |
| Feb 20, 2020 | 817 | 80 | 10.85% |
| Feb 20, 2019 | 737 | 190 | 34.73% |
| Feb 20, 2018 | 547 | 112 | 25.75% |
| Feb 21, 2017 | 435 | 7 | 1.64% |
| Feb 19, 2016 | 428 | 38 | 9.74% |
| Feb 17, 2015 | 390 | 86 | 28.29% |
| Feb 17, 2014 | 304 | 16 | 5.56% |
| Feb 11, 2013 | 288 | 7 | 2.49% |
| Feb 13, 2012 | 281 | 11 | 4.07% |
| Feb 14, 2011 | 270 | 20 | 8.00% |
| Feb 10, 2010 | 250 | -50 | -16.67% |
| Feb 10, 2009 | 300 | 0 | - |
| Mar 1, 2008 | 300 | 26 | 9.49% |
| Mar 5, 2007 | 274 | 16 | 6.20% |
| Mar 3, 2006 | 258 | -45 | -14.85% |
| Mar 3, 2005 | 303 | -154 | -33.70% |
| Mar 3, 2004 | 457 | -66 | -12.62% |
| Feb 28, 2003 | 523 | 89 | 20.51% |
| Feb 28, 2002 | 434 | 131 | 43.23% |
| Jan 31, 2001 | 303 | -49 | -13.92% |
| Feb 25, 2000 | 352 | 6 | 1.73% |
| Feb 26, 1999 | 346 | 8 | 2.37% |
| Feb 27, 1998 | 338 | 51 | 17.77% |
| Jan 31, 1997 | 287 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
IONS News
- 5 days ago - Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034 - GlobeNewsWire
- 7 days ago - Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum - PRNewsWire
- 12 days ago - Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 4 weeks ago - Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval - Seeking Alpha
- 4 weeks ago - FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood - Benzinga
- 4 weeks ago - TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet - PRNewsWire
- 4 weeks ago - US FDA approves Ionis Pharma's genetic disorder drug - Reuters
- 2 months ago - Ionis to present at upcoming investor conferences - PRNewsWire